Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Subjects:	soluble PD-L1 advanced non-small cell lung cancer PD-1 inhibitors individual patient data meta-analysis biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/full